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Synopsis
Inhibition of the PI3K (phosphoinositide 3-kinase)/Akt/mTORC1 (mammalian target of rapamycin complex 1) and
Ras/MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase]/ERK pathways
for cancer therapy has been pursued for over a decade with limited success. Emerging data have indicated that only
discrete subsets of cancer patients have favourable responses to these inhibitors. This is due to genetic mutations
that confer drug insensitivity and compensatory mechanisms. Therefore understanding of the feedback mecha-
nisms that occur with respect to specific genetic mutations may aid identification of novel biomarkers that predict
patient response. In the present paper, we show that feedback between the PI3K/Akt/mTORC1 and Ras/MEK/ERK
pathways is cell-line-specific and highly dependent on the activating mutation of K-Ras or overexpression c-Met. We
found that cell lines exhibited differential signalling and apoptotic responses to PD184352, a specific MEK inhibitor,
and PI103, a second-generation class I PI3K inhibitor. We reveal that feedback from the PI3K/Akt/mTORC1 to the
Ras/MEK/ERK pathway is present in cancer cells harbouring either K-Ras activating mutations or amplification of
c-Met but not the wild-type counterparts. Moreover, we demonstrate that inhibition of protein phosphatase activity
by OA (okadaic acid) restored PI103-mediated feedback in wild-type cells. Together, our results demonstrate a novel
mechanism for feedback between the PI3K/Akt/mTORC1 and the Ras/MEK/ERK pathways that only occurs in K-Ras
mutant and c-Met amplified cells but not the isogenic wild-type cells through a mechanism that may involve inhibition
of a specific endogenous phosphatase(s) activity. We conclude that monitoring K-Ras and c-Met status are important
biomarkers for determining the efficacy of PI103 and other PI3K/Akt inhibitors in cancer therapy.
Key words: Akt, cancer cell, c-Met, K-Ras, mitogen-activated protein kinase/extracellular-signal-regulated kinase
kinase (MEK), phosphoinositide 3-kinase (PI3K).
Cite this article as: Yuen, H.-F., Abramczyk, O., Montgomery, G., Chan, K.-K., Huang, Y.-H., Sasazuki, T., Shirasawa, S., Gopesh, S.,
Chan, K.-W, Fennell, D., Janne, P., El-Tanani, M. and Murray, J.T. (2012) Impact of oncogenic driver mutations on feedback between
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INTRODUCTION
The PI3K (phosphoinositide 3-kinase)/Akt/mTORC1 (mam-
malian target of rapamycin complex 1) and MEK [MAPK
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(mitogen-activated protein kinase)/ERK (extracellular-signal-
regulated kinase) kinase]/ERK pathways are the two major hyper-
activated pathways that promote cancer progression through
enhancing cell survival, metastasis and drug resistance. How-
ever, inhibition of either the PI3K/Akt/mTORC1 or MEK/ERK
C© 2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/
by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
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pathways for treatment of cancers has shown increasingly limited
success [1].
The development of anti-cancer drugs targeting MEK has been
investigated for more than a decade [2] and MEK inhibition im-
pairs colon tumour growth in vivo [3]. PD184352 (CI-1040) is
an orally active highly selective and potent chemical inhibitor
of MEK1/2 and was the first MEK inhibitor to enter clinical
trials [4]. Tumours with higher pERK (phospho-ERK) expres-
sion are marginally more responsive to PD184352, although the
overall anti-tumour activity of this drug is insufficient in mul-
tiple human cancers [5]. Promisingly, PD184352 was shown to
inhibit pERK in pancreatic cancer and lead to stable disease
with a median of 5.5 months in 28 % of patients [6]. Overall,
results from clinical trials indicate there are subsets of patients
that are non-responsive to PD184352, thus patient stratification
may prove effective in identifying PD184352 responders and
extend the usefulness of this drug. K-Ras status and cellular
background are important factors in determining sensitivity to
PD184352. The K-Ras mutant C26 murine colon cell line is
resistant to PD184352 [7], whereas thyroid cancer cells har-
bouring K-Ras and BRAF-activated mutations are more sens-
itive to PD184352 [8]. In addition, MEK inhibition results in
feedback activation of the PI3K/Akt pathway in MDA (malon-
dialdehyde) MB 231 breast cancer cells [9]. Finally, PD184352
also shows to produce synergistic therapeutic efficacy with other
chemotherapeutic drugs, including taxol [10], sorafenib [11] and
BMS-214662 [12].
The PI3K/Akt/mTORC1 pathway is a major focus for can-
cer therapy [13]. PI103 is a second generation inhibitor of class
I PI3K with anti-tumour activity in a variety of human can-
cers [14–16]. PI103 also enhances tumour radiosensitivity [17]
and chemosensitivity [18]. However, the use of PI103 is conten-
tious, since combined use with sorafenib promotes tumour growth
and survival in melanoma cells [19], but inhibits proliferation of
hepatocellular carcinoma cells [20].
Combinatorial use of PI3K/Akt/mTORC1 and MEK/ERK
pathway inhibitors synergistically induce apoptosis in MDA MB
231 and the hepatocellular carcinoma cell line Huh7 [9,20]. How-
ever, direct inhibition of PI3K also reportedly activates the HER2
receptor, thereby enhancing MEK/ERK signalling [21]. Given
the lack of clarity with the use of these inhibitors, especially
with the impact of genetic background on their effectiveness, a
thorough understanding of the chemical–genetic interactions is
required to improve the efficacy of therapies that target these
pathways.
In the present study, we have investigated inhibition of the
PI3K/Akt/mTORC1 and MEK/ERK pathways in a representat-
ive panel of breast, lung, prostate, oesophageal and colorectal cell
lines with known genetic backgrounds. In particular, we assessed
the molecular mechanisms of pathway feedback and cross-talk.
We report that pathway interactions are cell line-specific, with
cell lines having negative-feedback loops to either or both path-
ways. Furthermore, we found that K-Ras, c-Met and endogenous
protein phosphatase activity are crucial in regulating feedback
between the PI3K/Akt/mTORC1 pathway and the MEK/ERK
pathway.
MATERIALS AND METHODS
Cell culture
MDA MB 231, MDA MB 157 and Hs578t (breast; A.T.C.C.)
and A549 (lung; A.T.C.C.) cancer cell lines were maintained in
DMEM (Dulbecco’s modified Eagle’s medium) supplemented
with 10 % FBS (fetal bovine serum). T47D (breast; A.T.C.C.),
DU145 (prostate; A.T.C.C.), EC109 [22] (oesophageal; a gift
from Professor S.W. Tsao, Department of Anatomy, University of
Hong Kong, Hong Kong, China), and HCC827 and its c-Met amp-
lified counterpart HCC827-GR5 [23] (lung; from Professor P.A.
Janne, Dana-Farber Cancer Institute, Boston, MA, U.S.A.) cancer
cell lines were maintained in RPMI 1640 supplemented with 10 %
FBS. HCT116 (active K-Ras mutant) and its wild-type isogenic
counterpart Hkh-2 cells [24] (colon; from Professor T. Sasazuki,
Department of Genetics, Medical Institute of Bioregulation,
Kyushu University, Higashi, Japan, and Professor S. Shirasawa,
Department of Pathology, International Medical Center of
Japan, Tokyo, Japan) cancer cell lines were maintained in DMEM
supplemented with 10 % FBS and sodium pyruvate.
Kinase inhibitors
PI103 (Merck), a dual inhibitor of class I PI3K and mTORC1,
was used at a concentration of 10 μM. PD184352, a specific
MEK1/2 inhibitor, was a gift from Dr Rudi Marquez, University
of Glasgow, Glasgow, U.K. and was used at a concentration of
2 μM. Rapamycin was obtained from EMD Biosciences and used
at a concentration of 100 nM. OA (okadaic acid; Santa Cruz
Biotechnology) was used at a concentration of 20 nM.
Western blot analysis
Western blot analysis was performed as previously described
[25]. Anti-pAkt (phospho-Akt) (Ser473) (#4071), -Akt (#4691),
-pERK1/2 (#4370), -ERK (#4685), -PARP [poly(ADP-ribose)
polymerase] (#9544), -caspase 3 (#9662), -Bcl-XL (#2764) and
-cyclin D1 (#2926) antibodies (Cell Signaling Technology) were
used at a concentration of 1:1000, and the anti-actin antibody
(A1978; Sigma) was used at a concentration of 1:10 000.
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide] cell survival
assay
MTT assay was performed as described previously [26]. Briefly,
cells were seeded in a 96-well plate and allowed to grow for
24 h. Inhibitors were then added to the culture medium. At the
indicated time point, cells were incubated with MTT (Sigma) at
a concentration of 200 ng/ml for 4 h. The crystallized MTT was
then dissolved in DMSO (Sigma) and the absorbance at 595 nm
was recorded.
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Cross-talk between the PI3K/Akt and the MEK/ERK pathways
Figure 1 Feedback between the MEK/ERK and PI3K/Akt pathways in MDA MB 231 and A549 cells
(A) Phosphorylation of Akt and ERK in MDA MB 231 and A549 cells treated with PD184352 for 24, 48 and 72 h.
(B) Phosphorylation of Akt and ERK in MDA MB 231, T47D, Hs578T, MDA MB 157 (breast cancer) and A549 (lung cancer)
cells treated with PD184352 for 72 h. (C) Phosphorylation of Akt, ERK and expression of Bcl-XL in MDA MB 231 treated
with various combinations of inhibitors. (D) Phosphorylation of Akt and ERK in MDA MB 231 cells treated with PI103 for
24, 48 and 72 h. (E) Phosphorylation of Akt and ERK in A549 cells treated with PI103 for 24, 48 and 72 h. Representative
of three independent experiments.
RESULTS
Prolonged inhibition of the MEK/ERK pathway by
PD184352 up-regulates Akt phosphorylation
Previously, treatment of MDA MB 231 cells with PD184352
blocked pERK1/2 and enhanced pAkt, for up to 24 h [9]. In
the prsent study, up-regulation of pAkt was observed following
PD184352 treatment in MDA MB 231 at 24 h (Figure 1A) but fur-
ther increased at 48 and 72 h. Conversely, pAkt did not increase
substantially following treatment with PD184352 at 48 h, but was
increased at 72 h in A549 lung cancer cell line (Figure 1A). In
other breast cancer cell lines, including Hs578t and MDA MB
157, but not T47D cells, prolonged PD184352 treatment also in-
creased pAkt (Figure 1B). These results suggest that inhibition of
the MEK/ERK pathway feeds back on to the PI3K/Akt pathway,
in a cell-line-specific manner.
Inhibition of PI3K/Akt/mTORC1 pathway
up-regulates ERK1/2 phosphorylation
In both MDA MB 231 breast and A549 lung cancer cell
lines, at 24, 48 and 72 h post-treatment, PI103 inhibited
pAkt and increased pERK (Figures 1C and 1D). This was
recapitulated with siRNA (small interfering RNA) targeting
of Akt in MDA MB 231 cells, where reduced Akt expres-
sion also stimulated pERK (see Supplementary Figure S1 at
http://www.bioscirep.org/bsr/032/bsr0320413add.htm).
A PI3K/Akt-negative-feedback loop on to the MEK/ERK
pathway that is mTORC1 dependent is present in glioblastoma
cell lines [27]. Since PI103 is also known to inhibit mTORC1
activity [15], MDA MB 231 cells were exposed to PD184352
with or without serum and either PI103, the mTORC1 inhibitor
rapamycin, or combinations of inhibitors (Figure 1E) to investig-
ate whether the observed increase in pERK by PI103 is dependent
on the activity of mTORC1. Serum withdrawal did not abolish
PD184352-induced pAkt, suggesting that an extrinsic stimulus
is not required for the MEK/ERK to PI3K/Akt feedback. On
the other hand, pAkt was abolished and pERK was increased in
MDA MB 231 cells treated with PI103 (Figure 1E). Rapamy-
cin treatment also induced pERK in MDA MB 231 cells, but
not as effectively as PI103, suggesting that PI3K and mTORC1
activities are both required. MEK activation promotes expression
of Bcl-XL [28,29]. As expected, PD184352 treatment decreased
Bcl-XL expression, although neither rapamycin nor PI103, which
increased pERK, altered Bcl-XL expression (Figure 1E).
Feedback between the PI3K/Akt and MEK/ERK
pathways is cell-line-specific
To assess whether cross-talk is conserved in cancer cells of dif-
ferent origins, the effect of combining PD184352 with either
PI103 or rapamycin was examined in breast (MDA MB 231,
MDA MB 157 and Hs578t), lung (A549), prostate (DU145)
and oesophageal (EC109) cancer cell lines. As expected, treat-
ment with PD184352 inhibited pERK in all cell lines examined.
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Inhibition of pERK up-regulated pAkt in MDA MB 231
and MDA MB 157 cells, but less so in Hs578t, A549 and
DU145 cells (Figures 2A–2F). Surprisingly, in the oesophageal
cancer cell line EC109, a significant down-regulation of pAkt
was observed and was concomitant with decreased Akt protein
expression.
Conversely, treatment with PI103 resulted in inhibition of pAkt
in all the cell lines examined, as expected. It also led to an in-
crease in pERK in MDA MB 231, MDA MB 157, Hs578t, A549
and EC109 cells, but not in DU145 cells (Figures 2A–2F). In-
hibition of mTORC1 can reportedly activate the PI3K/Akt and
MEK/ERK pathways [27,30,31] in some cells, but inhibits the
PI3K/Akt pathway in others [32]. Rapamycin treatment slightly
increased pERK, without affecting pAkt in MDA MB 231 cells
(Figure 2A). However, in MDA MB 157, A549 and EC109 cells,
treatment with rapamycin resulted in increased pAkt, but pERK
was unaffected (Figures 2B, 2D and 2F), further suggesting that
class I PI3K inhibition is required to enhance pERK phosphoryla-
tion in these cell lines. In Hs578t cells, rapamycin treatment in-
creased pAkt, while pERK was decreased (Figure 2C). Finally, in
DU145 cells, rapamycin treatment had minimal affects on either
pAkt or pERK (Figure 2E). Together, our results suggest that
the PI3K/Akt and MEK/ERK negative-feedback loops are cell
line/genetic-context-specific.
Reduced cell survival following combined blockade
of both pathways
We next investigated whether inhibition of both of these path-
ways affected cell survival. In MDA MB 231 and A549 cells,
in addition to decreased pERK and Bcl-XL expression, cyclin
D1 expression was also decreased by PD184352 treatment and
completely abolished when PD184352 was combined with PI103
(Figures 2G and 2H). Treatment with PD184352 and PI103, but
not rapamycin, led to PARP and caspase 3 cleavage in both cell
lines as early as 24 h (Figures 2G and 2H). However, a combined
treatment of rapamycin and PD184 352 in A549 cells resulted in
a subtle increase in PARP cleavage, but not caspase 3, compared
with treatment with either inhibitor alone (Figure 2H). These res-
ults suggest that inhibition of both PI3K and MEK is required
for the observed synergistic activation of the apoptotic signalling
pathway.
Cell survival was assessed by MTT assay to determine whether
treatment of cells with PD184352 alone, or in combination with
PI103 or rapamycin was inhibitory. PD184352 treatment reduced
cell survival by 50 % in MDA MB 231 cells (Figure 2I), but
not A549 cells (Figure 2J). Rapamycin treatment did not af-
fect survival of either MDA MB 231 or A549 cells, but when
combined with PD184352, survival was slightly reduced com-
pared with PD18453 alone, in both cell lines (Figures 2I and
2J). PI103 treatment severely impaired cell survival in MDA
MB 231 and A549 cells by 60 and 80 % respectively, and this
was further reduced when combined with PD184352 treatment
(Figures 2I and 2J). Combined treatment with PI3K and MEK in-
hibitors is more efficient at inhibiting cell survival and promoting
apoptosis.
K-Ras status affects feedback between the
PI3K/Akt and MEK/ERK pathways
K-Ras mutations drive hyper-activation of the MEK/ERK path-
way to increase cell proliferation and are associated with
drug resistance in most human cancers. Treatment of K-Ras-
activating mutant HCT116 cells with PD184352, with or without
serum, inhibited pERK and up-regulated pAkt at 24 and 48 h
(Figures 3A–3C). Conversely, PI103 inhibited pAkt but also in-
creased pERK (Figures 3A–3C, and Supplementary Figure S2
at http://www.bioscirep.org/bsr/032/bsr0320413add.htm). In
Hkh-2 cells that are K-Ras wild-type treatment with PD184352
also down-regulated pERK and enhanced pAkt in the pres-
ence (Figures 3D and 3E) or absence (Figure 3F) of
serum. However, in Hkh-2, irrespective of serum withdrawal,
PI103 down-regulated pAkt while pERK was unaffected
(Figures 3D–3F, and Supplementary Figure S2). Similar res-
ults were also observed in a second colorectal isogenic cell line
pair, DLD1/DKO3, where DKO3 also showed no sensitivity to
PI103, unlike DLD1 cells (see Supplementary Figure S3 at http://
www.bioscirep.org/bsr/032/bsr0320413add.htm). Thus the K-
Ras mutation is required for the activation of MEK/ERK pathway
upon PI103-dependent inhibition of the PI3K/Akt pathway.
K-Ras status affects cell apoptosis and survival
Western blot analysis of PARP and caspase 3 cleavage showed
that K-Ras wild-type Hkh-2 cells were more sensitive to PI103
than K-Ras mutant HCT116 cells (Figure 3). Thus sensitivity of
the HCT116/Hkh-2 isogenic cells to treatment with PD184352,
PI103 and both drugs together was assessed in a cell survival
assay. Treatment with PD184352 alone reduced the percentage
of surviving cells in both cell lines to a similar extent, and this
was more obvious at 48 h (Figure 4). Similarly, PI103 also re-
duced cell survival but more potently in Hkh-2 than HCT116
cells and this was also more apparent at 48 h. Combined treat-
ment with PI103 and PD184352 at 48 h also had a more profound
effect on cell survival in Hkh-2 cells (Figure 4). Thus a K-Ras
activating mutation confers resistance to PI103 and a combinat-
orial inhibition of both the PI3K/Akt and MEK/ERK pathways
may enhance the apoptotic response in cancer cells harbouring a
K-Ras activating mutation.
c-Met amplification affects drug responses in
HCC827 lung cancer cells
The HCC827 lung cancer cell line and its gefitinib-resistant deriv-
ative GR5 cell line (amplified c-Met), were used to investigate the
effect of c-Met amplification on drug sensitivity. Amplification
of c-Met in HCC827 (GR5) cells caused up-regulation of pAkt
and pERK (Figure 5A). Treatment with PD184352 suppressed
pERK and up-regulated pAkt in both cell lines, irrespective of c-
Met amplification (Figure 5A). However, PI103 treatment down-
regulated pAkt, but did not up-regulate pERK in HCC827 cells,
unlike GR5 cells (Figure 5A). Thus c-Met amplification sensit-
izes cells to MEK/ERK pathway activation following inhibition
of the PI3K/Akt/mTORC1 pathway by PI103 and renders them
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Cross-talk between the PI3K/Akt and the MEK/ERK pathways
Figure 2 Differential sensitivities to drug-induced apoptosis in cancer cell lines
(A–F) Akt and ERK phosphorylation and expression of PARP in (A) MDA MB 231 (breast), (B) MDA MB 157 (breast),
(C) Hs578t (breast), (D) A549 (lung), (E) DU145 (prostate) and (F) EC109 (oesophageal) cancer cell lines treated with
PD184352 and PI103 alone or in combination. (G and H) Akt and ERK phosphorylation and expression of PARP, cleaved
caspase 3, Bcl-XL and cyclin D1 in (G) MDA MB 231 and (H) A549 cells treated with various combinations of PD184352,
PI103 and rapamycin. MTT cell survival assay for (I) MDA MB 231 and (J) A549 cancer cells treated with various
combinations of PD184352, PI103 and rapamycin. Representative of three independent experiments, error bars are S.D.
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Figure 3 K-Ras status affects response to PD184352 and PI103
Expression of PARP, pAkt, pERK, cleaved caspase 3 in K-Ras mutant
HCT116 or wild-type Hkh-2 cells treated with PD184352 or PI103 for 24
(A and D) and 48 h (B and E) in the presence of serum or in serum-free
conditions (C and F). Representative of three independent experiments.
less susceptible to PI103-induced apoptosis, with higher levels of
cleaved PARP and caspase 3 detected at 24 and 48 h in HCC827
cells, compared with GR5 cells (Figure 5A).
Figure 4 K-Ras mutation desensitizes HCT116 cells to PI103
MTT cell survival assay in HCT116 and Hkh-2 cells treated with or
without PD184352 and PI103 alone or in combination for 24 and 48 h.
Representative of three independent experiments, error bars are S.D.
Inhibition of mTORC1 by rapamycin alone increased pERK
in HCC827 cells, but was insufficient to up-regulate pERK in
GR5 cells, compared with PI103 (Figure 5B). Combined use of
both PD184352 and PI103 blocked both pathways and induced
a synergistic induction of apoptosis in both cell lines and this
synergistic effect was more potent in GR5 cells (Figure 5B).
These results suggest that a combination treatment of PI3K and
MEK inhibitors may give rise to a better killing effect in c-Met
amplified cells, in which both negative-feedback loops are active.
OA restores PI103-dependent pERK activation in
K-Ras wild-type Hkh-2 and c-Met wild-type HCC827
cancer cells
Drug-induced feedback activities can be controlled by either
kinase or phosphatase activities. We assessed whether a phos-
phatase activity is participating in the feedback networks in
the two pairs of isogenic cancer cell lines. In wild-type
K-Ras harbouring Hkh-2 cells and c-Met normal HCC827 cells,
PI103 treatment did not increase pERK, while PI103 did in their
K-Ras mutant and c-Met amplified counterparts. PI103-induced
pERK in HCT116 and GR5 cells was substantially increased in
the presence of OA, although OA also increased basal pERK
in both control and rapamycin-treated cells (Figures 6A and
6C). In Hkh-2 and HCC827 cells, OA also increased basal pERK
in both control and rapamycin-treated cells, but in contrast, while
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
418 C© 2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/
by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
Cross-talk between the PI3K/Akt and the MEK/ERK pathways
Figure 5 Amplification of c-Met confers resistance to PI103-induced apoptosis through increased ERK phosphorylation
(A) Akt and ERK phosphorylation and expression of PARP and cleaved caspase 3 in HCC827 and GR5 lung cancer cells
treated with or without PD184352 or PI103 at 24 and 48 h. (B) Akt and ERK phosphorylation and expression levels of
PARP and cleaved caspase 3 in HCC827 and GR5 lung cancer cells treated with or without either PI103 or rapamycin
alone, or in combination with PD184352. Representative of three independent experiments.
Figure 6 OA enhances PI103-stimulated ERK phosphorylation
ERK phosphorylation in HCT116 (A), Hkh-2 (B), HCC827 (C) and GR5 (D) cells treated with PI103, PD184352 or rapamycin
with or without OA. Representative of three independent experiments.
PI103 alone failed to induce pERK, co-incubation of PI103 with
OA further increased pERK compared with control (Figures 6B
and 6D). These results suggest that the intrinsic phosphatase
activities may be required to suppress the PI3K/Akt to MEK/ERK
feedback loop.
DISCUSSION
In the present study, we provide evidence for cell-line-specific
feedback mechanisms that predict sensitivity to combined thera-
peutic targeting of the PI3K/Akt/mTORC1 and Ras/MEK/ERK
signalling pathways. Using K-Ras active/wild-type isogenic
cells and c-Met amplified cells, we reveal that activating K-Ras
mutations and c-Met amplification facilitate enhanced activation
of the Ras/MEK/ERK pathway, following inhibition of the
PI3K/Akt/mTORC1 pathway. Activation of this feedback mech-
anism appears to be required for protection from apoptosis and
hence cell survival in the presence of PI103 alone, since com-
bined treatment with PI103 and PD184352 abrogates this cyto-
protective effect. In addition, the importance of phosphatase(s)
in this regulatory loop has also been demonstrated in the present
study. Our results show that determination of both genetic
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background and whether these feedback mechanisms are active
in cancers will inform treatment decisions. Mechanistically, we
show that inhibition of the PI3K/Akt/mTORC1 pathway leads
to activation of the Ras/MEK/ERK signalling cascade and this
is dictated by K-Ras and c-Met status and protein phosphatase
activity.
Active K-Ras harbouring HCT116 cells are more resistant
to inhibition of PI3K/Akt/mTORC1 pathway than its wild-type
K-Ras derivative Hkh-2 cells, which do not exhibit increased
pERK following PI103 treatment. Similar results were observed
in another isogenic cell line pair, DLD1/DKO3, where DKO3
also showed no sensitivity to PI103, unlike DLD1 cells (Supple-
mentary Figure S3). HCT116 parental cells harbour a PIK3CA
gain-of-function mutation, whereas DLD1 parental cells do not,
suggesting that K-Ras mutations dictate sensitivity to PI103.
Indeed, this is consistent with a mouse lung cancer model that
is driven by mutant K-Ras; the tumour was not substantially
responsive to a dual PI3K and mTORC1 inhibitor, NVP-BEZ235,
but was synergistically inhibited by combined treatment of both
NVP-BEZ235 and a MEK inhibitor, ARRY-142886 [33]. Thus
we may have provided a molecular mechanism that explains the
observation reported by Engelman et al. We propose that can-
cer cells harbouring active K-Ras mutations are able to activate
ERK in response to PI3K/Akt/mTORC1 pathway inhibition. This
negative-feedback loop is cytoprotective, thus combined inhibi-
tion of both pathways abrogates the negative-feedback loop, res-
ulting in synergistic induction of apoptosis. Our results suggest
that the efficacy of PI103 or other PI3K/Akt/mTORC1 pathway
inhibitors would be greater in K-Ras wild-type patients.
Amplified c-Met signalling promotes cancer cell survival by
activating both the PI3K/Akt/mTORC1 and the Ras/MEK/ERK
pathways [34]. In a recent report, an HGF (human growth factor)-
stimulated (c-Met agonist), gefitinib [EGFR (epidermal growth
factor receptor) inhibitor] resistant, xenograft model for lung
cancer was shown to be resistant to PI103 alone but was highly
sensitive to combined treatment with PI103 and gefitinib [35].
Their results suggest that enhanced methionine receptor sig-
nalling following HGF treatment in lung cancer cells results
in resistance to the inhibition of the PI3K/Akt/mTORC1 path-
way by PI103. We show that c-Met amplification in GR5 cells
generates a negative-feedback loop from the PI3K/Akt/mTORC1
pathway to the Ras/MEK/ERK pathway, which is absent in the
parental isogenic HCC827 cells. Importantly, GR5 cells are also
more resistant to inhibition of the PI3K/Akt/mTORC1 pathway
compared with HCC827 cells. We further show that combined
inhibition of these pathways, by PI103 and PD184352, synergist-
ically induces the apoptotic pathway in GR5 cells. Our results,
therefore suggest that c-Met amplification and signalling may
be a biomarker for determining the sensitivity of lung cancers
to PI3K/Akt/mTORC1 inhibitors and that a combinatorial inhib-
ition of these pathways will be more effective in lung cancers
with c-Met amplification.
The Ras/MEK/ERK pathway is regulated by various phos-
phatases, including VHR (vaccinia H1-related) phosphatase [36],
protein phosphatase 5 [37], MAPK phosphatase [38] and DUSP6
(dual-specific phosphatase 6) [39]. DUSP6 is also involved in
cross-talk between mTORC1 and the Ras/MEK/ERK pathway
[40]. In the present study, we show that the PP1 and PP2A/B
phosphatase inhibitor, OA, restored the PI103-dependent in-
crease in pERK in K-Ras wild-type and c-Met normal cells.
This may be through accumulation of pAkt; however, PI103 acts
on both PI3K, upstream of Akt and also on mTORC1 and mT-
ORC2, while siRNA of Akt increased pERK, at least in MDA
MB 231 cells. Thus accumulation of Akt phosphorylation, and
therefore increased Akt activity, as a result of phosphatase in-
hibition is unlikely to cause increased pERK. Thus we propose
that a protein phosphatase(s) activity is present or activated in
K-Ras wild-type and c-Met normal cells preventing feedback
from the PI3K/Akt/mTORC1 pathway to the Ras/MEK/ERK
pathways. Conversely, this phosphatase activity is inhibited in
K-Ras mutant or c-Met amplified cells, thereby preventing atten-
uation of ERK phosphorylation. Furthermore, identification of
the phosphatase(s) activity that is involved may provide a useful
biomarker that could distinguish PI3K/Akt/mTORC1-inhibitor-
sensitive and-insensitive cancers and whether a combined inhib-
ition of both pathways could be beneficial to the patients.
In conclusion, we report the importance of K-Ras muta-
tion or c-Met amplification in controlling feedback from the
PI3K/Akt/mTORC1 to Ras/MEK/ERK pathways. We have tested
a number of cell lines of breast and colorectal origin and the phe-
nomenon of cross-talk appears to be common, at least in the
cell types we have examined. We argue that genetic subtyping of
primary tumours for K-Ras mutation or c-Met amplifications will
be valuable predictors of tumour response to PI3K/Akt/mTORC1
pathway inhibition. This approach will allow for patient strati-
fication and tailored therapeutic choices, ultimately improving
patient response rates and outcome.
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Figure S1 Effect of knockdown of Akt by siAkt on total Akt and
ERK phosphorylation
Akt was knocked down in MDA MB231 breast cancer cell line by siAkt
(Cell Signaling Technology). Expression levels of total Akt, total and
phosphorylated ERK and actin were examined by Western immunoblot-
ting. Akt expression was almost completely abolished and ERK phos-
phorylation, but not the total ERK, was increased.
1 Present address: Trinity Biomedical Sciences Institute, School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland.
2 Correspondence may be addressed to either of these authors (email j.t.murray@qub.ac.uk or m.el-tanani@qub.ac.uk).
Figure S2 Effect of inhibitors on Akt and ERK1/2 phosphorylation
HCT116 and Hkh-2 cells were treated with various combinations of
PI103, PD184352 and rapamycin. Phosphorylation of Akt and ERK was
examined by Western immunoblotting. Increased ERK phosphorylation
was observed following PI103 treatment in HCT116, but not Hkh-2,
cells. Co-treatment with PI103 and PD184352 abolished Akt and ERK
phosphorylation.
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Figure S3 K-Ras status affects response to PD184352 and
PI103 in a second colorectal cancer isogenic pair
Expression of PARP, pAkt, pERK, cleaved caspase 3 in K-Ras mutant
DLD1 or wild-type DKO3 cells treated with PD184352 or PI103 for 24
(A and D) and 48 h (B and E) in the presence of serum or in serum-free
conditions (C and F). Representative of three independent experiments.
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